

# **2023-2028 Global and Regional PD-1/PD-L1 Immunotherapy Industry Status and Prospects Professional Market Research Report Standard Version**

<https://marketpublishers.com/r/2BC0A8B7FDD0EN.html>

Date: April 2023

Pages: 162

Price: US\$ 3,500.00 (Single User License)

ID: 2BC0A8B7FDD0EN

## **Abstracts**

The global PD-1/PD-L1 Immunotherapy market is expected to reach US\$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.

The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market vendors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America).

By Market Vendors:

AstraZeneca Plc

Innovent Biologics, Inc.

Chia Tai Tianqing Pharmaceutical Group Co. Ltd.

BeiGene, Ltd.

GlaxoSmithKline plc

Bristol-Myers Squibb Company

Merck & Co., Inc.

F. Hoffmann-La Roche Ltd

Eli Lilly & Company

Jiangsu HengRui Medicine Co., Ltd.

Novartis AG

Sanofi S.A.

Pfizer Inc.

## Regeneron Pharmaceuticals Inc.

### By Types:

PD-1 Inhibitors

PD-L1 Inhibitors

### By Applications:

Non-Small Cell Lung Cancer

Esophageal Cancer

Urothelial Carcinoma

Hepatocellular Carcinoma

Small Cell Lung Cancer

Others

### Key Indicators Analysed

**Market Players & Competitor Analysis:** The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2017-2028 & Sales with a thorough analysis of the market's competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.

**Global and Regional Market Analysis:** The report includes Global & Regional market status and outlook 2017-2028. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.

**Market Trends:** Market key trends which include Increased Competition and Continuous Innovations.

**Opportunities and Drivers:** Identifying the Growing Demands and New Technology

**Porters Five Force Analysis:** The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

### Key Reasons to Purchase

To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.

Assess the production processes, major issues, and solutions to mitigate the development risk.

To understand the most affecting driving and restraining forces in the market and its impact in the global market.

Learn about the market strategies that are being adopted by leading respective organizations.

To understand the future outlook and prospects for the market.

Besides the standard structure reports, we also provide custom research according to specific requirements.

## Contents

### CHAPTER 1 INDUSTRY OVERVIEW

- 1.1 Definition
- 1.2 Assumptions
- 1.3 Research Scope
- 1.4 Market Analysis by Regions
  - 1.4.1 North America Market States and Outlook (2023-2028)
  - 1.4.2 East Asia Market States and Outlook (2023-2028)
  - 1.4.3 Europe Market States and Outlook (2023-2028)
  - 1.4.4 South Asia Market States and Outlook (2023-2028)
  - 1.4.5 Southeast Asia Market States and Outlook (2023-2028)
  - 1.4.6 Middle East Market States and Outlook (2023-2028)
  - 1.4.7 Africa Market States and Outlook (2023-2028)
  - 1.4.8 Oceania Market States and Outlook (2023-2028)
  - 1.4.9 South America Market States and Outlook (2023-2028)
- 1.5 Global PD-1/PD-L1 Immunotherapy Market Size Analysis from 2023 to 2028
  - 1.5.1 Global PD-1/PD-L1 Immunotherapy Market Size Analysis from 2023 to 2028 by Consumption Volume
  - 1.5.2 Global PD-1/PD-L1 Immunotherapy Market Size Analysis from 2023 to 2028 by Value
  - 1.5.3 Global PD-1/PD-L1 Immunotherapy Price Trends Analysis from 2023 to 2028
- 1.6 COVID-19 Outbreak: PD-1/PD-L1 Immunotherapy Industry Impact

### CHAPTER 2 GLOBAL PD-1/PD-L1 IMMUNOTHERAPY COMPETITION BY TYPES, APPLICATIONS, AND TOP REGIONS AND COUNTRIES

- 2.1 Global PD-1/PD-L1 Immunotherapy (Volume and Value) by Type
  - 2.1.1 Global PD-1/PD-L1 Immunotherapy Consumption and Market Share by Type (2017-2022)
  - 2.1.2 Global PD-1/PD-L1 Immunotherapy Revenue and Market Share by Type (2017-2022)
- 2.2 Global PD-1/PD-L1 Immunotherapy (Volume and Value) by Application
  - 2.2.1 Global PD-1/PD-L1 Immunotherapy Consumption and Market Share by Application (2017-2022)
  - 2.2.2 Global PD-1/PD-L1 Immunotherapy Revenue and Market Share by Application (2017-2022)
- 2.3 Global PD-1/PD-L1 Immunotherapy (Volume and Value) by Regions

2.3.1 Global PD-1/PD-L1 Immunotherapy Consumption and Market Share by Regions (2017-2022)

2.3.2 Global PD-1/PD-L1 Immunotherapy Revenue and Market Share by Regions (2017-2022)

## **CHAPTER 3 PRODUCTION MARKET ANALYSIS**

3.1 Global Production Market Analysis

3.1.1 2017-2022 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis

3.1.2 2017-2022 Major Manufacturers Performance and Market Share

3.2 Regional Production Market Analysis

3.2.1 2017-2022 Regional Market Performance and Market Share

3.2.2 North America Market

3.2.3 East Asia Market

3.2.4 Europe Market

3.2.5 South Asia Market

3.2.6 Southeast Asia Market

3.2.7 Middle East Market

3.2.8 Africa Market

3.2.9 Oceania Market

3.2.10 South America Market

3.2.11 Rest of the World Market

## **CHAPTER 4 GLOBAL PD-1/PD-L1 IMMUNOTHERAPY SALES, CONSUMPTION, EXPORT, IMPORT BY REGIONS (2017-2022)**

4.1 Global PD-1/PD-L1 Immunotherapy Consumption by Regions (2017-2022)

4.2 North America PD-1/PD-L1 Immunotherapy Sales, Consumption, Export, Import (2017-2022)

4.3 East Asia PD-1/PD-L1 Immunotherapy Sales, Consumption, Export, Import (2017-2022)

4.4 Europe PD-1/PD-L1 Immunotherapy Sales, Consumption, Export, Import (2017-2022)

4.5 South Asia PD-1/PD-L1 Immunotherapy Sales, Consumption, Export, Import (2017-2022)

4.6 Southeast Asia PD-1/PD-L1 Immunotherapy Sales, Consumption, Export, Import (2017-2022)

4.7 Middle East PD-1/PD-L1 Immunotherapy Sales, Consumption, Export, Import

(2017-2022)

4.8 Africa PD-1/PD-L1 Immunotherapy Sales, Consumption, Export, Import (2017-2022)

4.9 Oceania PD-1/PD-L1 Immunotherapy Sales, Consumption, Export, Import  
(2017-2022)

4.10 South America PD-1/PD-L1 Immunotherapy Sales, Consumption, Export, Import  
(2017-2022)

## **CHAPTER 5 NORTH AMERICA PD-1/PD-L1 IMMUNOTHERAPY MARKET ANALYSIS**

5.1 North America PD-1/PD-L1 Immunotherapy Consumption and Value Analysis

5.1.1 North America PD-1/PD-L1 Immunotherapy Market Under COVID-19

5.2 North America PD-1/PD-L1 Immunotherapy Consumption Volume by Types

5.3 North America PD-1/PD-L1 Immunotherapy Consumption Structure by Application

5.4 North America PD-1/PD-L1 Immunotherapy Consumption by Top Countries

5.4.1 United States PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

5.4.2 Canada PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

5.4.3 Mexico PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

## **CHAPTER 6 EAST ASIA PD-1/PD-L1 IMMUNOTHERAPY MARKET ANALYSIS**

6.1 East Asia PD-1/PD-L1 Immunotherapy Consumption and Value Analysis

6.1.1 East Asia PD-1/PD-L1 Immunotherapy Market Under COVID-19

6.2 East Asia PD-1/PD-L1 Immunotherapy Consumption Volume by Types

6.3 East Asia PD-1/PD-L1 Immunotherapy Consumption Structure by Application

6.4 East Asia PD-1/PD-L1 Immunotherapy Consumption by Top Countries

6.4.1 China PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

6.4.2 Japan PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

6.4.3 South Korea PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

## **CHAPTER 7 EUROPE PD-1/PD-L1 IMMUNOTHERAPY MARKET ANALYSIS**

7.1 Europe PD-1/PD-L1 Immunotherapy Consumption and Value Analysis

7.1.1 Europe PD-1/PD-L1 Immunotherapy Market Under COVID-19

7.2 Europe PD-1/PD-L1 Immunotherapy Consumption Volume by Types

7.3 Europe PD-1/PD-L1 Immunotherapy Consumption Structure by Application

7.4 Europe PD-1/PD-L1 Immunotherapy Consumption by Top Countries

- 7.4.1 Germany PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022
- 7.4.2 UK PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022
- 7.4.3 France PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022
- 7.4.4 Italy PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022
- 7.4.5 Russia PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022
- 7.4.6 Spain PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022
- 7.4.7 Netherlands PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022
- 7.4.8 Switzerland PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022
- 7.4.9 Poland PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

## **CHAPTER 8 SOUTH ASIA PD-1/PD-L1 IMMUNOTHERAPY MARKET ANALYSIS**

- 8.1 South Asia PD-1/PD-L1 Immunotherapy Consumption and Value Analysis
  - 8.1.1 South Asia PD-1/PD-L1 Immunotherapy Market Under COVID-19
- 8.2 South Asia PD-1/PD-L1 Immunotherapy Consumption Volume by Types
- 8.3 South Asia PD-1/PD-L1 Immunotherapy Consumption Structure by Application
- 8.4 South Asia PD-1/PD-L1 Immunotherapy Consumption by Top Countries
  - 8.4.1 India PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022
  - 8.4.2 Pakistan PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022
  - 8.4.3 Bangladesh PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

## **CHAPTER 9 SOUTHEAST ASIA PD-1/PD-L1 IMMUNOTHERAPY MARKET ANALYSIS**

- 9.1 Southeast Asia PD-1/PD-L1 Immunotherapy Consumption and Value Analysis
  - 9.1.1 Southeast Asia PD-1/PD-L1 Immunotherapy Market Under COVID-19
- 9.2 Southeast Asia PD-1/PD-L1 Immunotherapy Consumption Volume by Types
- 9.3 Southeast Asia PD-1/PD-L1 Immunotherapy Consumption Structure by Application
- 9.4 Southeast Asia PD-1/PD-L1 Immunotherapy Consumption by Top Countries
  - 9.4.1 Indonesia PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022
  - 9.4.2 Thailand PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022
  - 9.4.3 Singapore PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022
  - 9.4.4 Malaysia PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022
  - 9.4.5 Philippines PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022
  - 9.4.6 Vietnam PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

#### 9.4.7 Myanmar PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

### **CHAPTER 10 MIDDLE EAST PD-1/PD-L1 IMMUNOTHERAPY MARKET ANALYSIS**

#### 10.1 Middle East PD-1/PD-L1 Immunotherapy Consumption and Value Analysis

##### 10.1.1 Middle East PD-1/PD-L1 Immunotherapy Market Under COVID-19

#### 10.2 Middle East PD-1/PD-L1 Immunotherapy Consumption Volume by Types

#### 10.3 Middle East PD-1/PD-L1 Immunotherapy Consumption Structure by Application

#### 10.4 Middle East PD-1/PD-L1 Immunotherapy Consumption by Top Countries

##### 10.4.1 Turkey PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

##### 10.4.2 Saudi Arabia PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

##### 10.4.3 Iran PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

##### 10.4.4 United Arab Emirates PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

##### 10.4.5 Israel PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

##### 10.4.6 Iraq PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

##### 10.4.7 Qatar PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

##### 10.4.8 Kuwait PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

##### 10.4.9 Oman PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

### **CHAPTER 11 AFRICA PD-1/PD-L1 IMMUNOTHERAPY MARKET ANALYSIS**

#### 11.1 Africa PD-1/PD-L1 Immunotherapy Consumption and Value Analysis

##### 11.1.1 Africa PD-1/PD-L1 Immunotherapy Market Under COVID-19

#### 11.2 Africa PD-1/PD-L1 Immunotherapy Consumption Volume by Types

#### 11.3 Africa PD-1/PD-L1 Immunotherapy Consumption Structure by Application

#### 11.4 Africa PD-1/PD-L1 Immunotherapy Consumption by Top Countries

##### 11.4.1 Nigeria PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

##### 11.4.2 South Africa PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

##### 11.4.3 Egypt PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

##### 11.4.4 Algeria PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

##### 11.4.5 Morocco PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

### **CHAPTER 12 OCEANIA PD-1/PD-L1 IMMUNOTHERAPY MARKET ANALYSIS**

#### 12.1 Oceania PD-1/PD-L1 Immunotherapy Consumption and Value Analysis

#### 12.2 Oceania PD-1/PD-L1 Immunotherapy Consumption Volume by Types

12.3 Oceania PD-1/PD-L1 Immunotherapy Consumption Structure by Application

12.4 Oceania PD-1/PD-L1 Immunotherapy Consumption by Top Countries

12.4.1 Australia PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

12.4.2 New Zealand PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

## **CHAPTER 13 SOUTH AMERICA PD-1/PD-L1 IMMUNOTHERAPY MARKET ANALYSIS**

13.1 South America PD-1/PD-L1 Immunotherapy Consumption and Value Analysis

13.1.1 South America PD-1/PD-L1 Immunotherapy Market Under COVID-19

13.2 South America PD-1/PD-L1 Immunotherapy Consumption Volume by Types

13.3 South America PD-1/PD-L1 Immunotherapy Consumption Structure by Application

13.4 South America PD-1/PD-L1 Immunotherapy Consumption Volume by Major Countries

13.4.1 Brazil PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

13.4.2 Argentina PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

13.4.3 Columbia PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

13.4.4 Chile PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

13.4.5 Venezuela PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

13.4.6 Peru PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

13.4.7 Puerto Rico PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

13.4.8 Ecuador PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

## **CHAPTER 14 COMPANY PROFILES AND KEY FIGURES IN PD-1/PD-L1 IMMUNOTHERAPY BUSINESS**

14.1 AstraZeneca Plc

14.1.1 AstraZeneca Plc Company Profile

14.1.2 AstraZeneca Plc PD-1/PD-L1 Immunotherapy Product Specification

14.1.3 AstraZeneca Plc PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2017-2022)

14.2 Innovent Biologics, Inc.

14.2.1 Innovent Biologics, Inc. Company Profile

14.2.2 Innovent Biologics, Inc. PD-1/PD-L1 Immunotherapy Product Specification

14.2.3 Innovent Biologics, Inc. PD-1/PD-L1 Immunotherapy Production Capacity,

## Revenue, Price and Gross Margin (2017-2022)

### 14.3 Chia Tai Tianqing Pharmaceutical Group Co. Ltd.

#### 14.3.1 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Company Profile

#### 14.3.2 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1/PD-L1 Immunotherapy Product Specification

#### 14.3.3 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2017-2022)

### 14.4 BeiGene, Ltd.

#### 14.4.1 BeiGene, Ltd. Company Profile

#### 14.4.2 BeiGene, Ltd. PD-1/PD-L1 Immunotherapy Product Specification

#### 14.4.3 BeiGene, Ltd. PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2017-2022)

### 14.5 GlaxoSmithKline plc

#### 14.5.1 GlaxoSmithKline plc Company Profile

#### 14.5.2 GlaxoSmithKline plc PD-1/PD-L1 Immunotherapy Product Specification

#### 14.5.3 GlaxoSmithKline plc PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2017-2022)

### 14.6 Bristol-Myers Squibb Company

#### 14.6.1 Bristol-Myers Squibb Company Company Profile

#### 14.6.2 Bristol-Myers Squibb Company PD-1/PD-L1 Immunotherapy Product Specification

#### 14.6.3 Bristol-Myers Squibb Company PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2017-2022)

### 14.7 Merck & Co., Inc.

#### 14.7.1 Merck & Co., Inc. Company Profile

#### 14.7.2 Merck & Co., Inc. PD-1/PD-L1 Immunotherapy Product Specification

#### 14.7.3 Merck & Co., Inc. PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2017-2022)

### 14.8 F. Hoffmann-La Roche Ltd

#### 14.8.1 F. Hoffmann-La Roche Ltd Company Profile

#### 14.8.2 F. Hoffmann-La Roche Ltd PD-1/PD-L1 Immunotherapy Product Specification

#### 14.8.3 F. Hoffmann-La Roche Ltd PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2017-2022)

### 14.9 Eli Lilly & Company

#### 14.9.1 Eli Lilly & Company Company Profile

#### 14.9.2 Eli Lilly & Company PD-1/PD-L1 Immunotherapy Product Specification

#### 14.9.3 Eli Lilly & Company PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2017-2022)

### 14.10 Jiangsu HengRui Medicine Co., Ltd.

- 14.10.1 Jiangsu HengRui Medicine Co., Ltd. Company Profile
- 14.10.2 Jiangsu HengRui Medicine Co., Ltd. PD-1/PD-L1 Immunotherapy Product Specification
- 14.10.3 Jiangsu HengRui Medicine Co., Ltd. PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2017-2022)
- 14.11 Novartis AG
  - 14.11.1 Novartis AG Company Profile
  - 14.11.2 Novartis AG PD-1/PD-L1 Immunotherapy Product Specification
  - 14.11.3 Novartis AG PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2017-2022)
- 14.12 Sanofi S.A.
  - 14.12.1 Sanofi S.A. Company Profile
  - 14.12.2 Sanofi S.A. PD-1/PD-L1 Immunotherapy Product Specification
  - 14.12.3 Sanofi S.A. PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2017-2022)
- 14.13 Pfizer Inc.
  - 14.13.1 Pfizer Inc. Company Profile
  - 14.13.2 Pfizer Inc. PD-1/PD-L1 Immunotherapy Product Specification
  - 14.13.3 Pfizer Inc. PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2017-2022)
- 14.14 Regeneron Pharmaceuticals Inc.
  - 14.14.1 Regeneron Pharmaceuticals Inc. Company Profile
  - 14.14.2 Regeneron Pharmaceuticals Inc. PD-1/PD-L1 Immunotherapy Product Specification
  - 14.14.3 Regeneron Pharmaceuticals Inc. PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2017-2022)

## **CHAPTER 15 GLOBAL PD-1/PD-L1 IMMUNOTHERAPY MARKET FORECAST (2023-2028)**

- 15.1 Global PD-1/PD-L1 Immunotherapy Consumption Volume, Revenue and Price Forecast (2023-2028)
  - 15.1.1 Global PD-1/PD-L1 Immunotherapy Consumption Volume and Growth Rate Forecast (2023-2028)
  - 15.1.2 Global PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)
- 15.2 Global PD-1/PD-L1 Immunotherapy Consumption Volume, Value and Growth Rate Forecast by Region (2023-2028)
  - 15.2.1 Global PD-1/PD-L1 Immunotherapy Consumption Volume and Growth Rate

## Forecast by Regions (2023-2028)

15.2.2 Global PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast by Regions (2023-2028)

15.2.3 North America PD-1/PD-L1 Immunotherapy Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)

15.2.4 East Asia PD-1/PD-L1 Immunotherapy Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)

15.2.5 Europe PD-1/PD-L1 Immunotherapy Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)

15.2.6 South Asia PD-1/PD-L1 Immunotherapy Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)

15.2.7 Southeast Asia PD-1/PD-L1 Immunotherapy Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)

15.2.8 Middle East PD-1/PD-L1 Immunotherapy Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)

15.2.9 Africa PD-1/PD-L1 Immunotherapy Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)

15.2.10 Oceania PD-1/PD-L1 Immunotherapy Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)

15.2.11 South America PD-1/PD-L1 Immunotherapy Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)

15.3 Global PD-1/PD-L1 Immunotherapy Consumption Volume, Revenue and Price Forecast by Type (2023-2028)

15.3.1 Global PD-1/PD-L1 Immunotherapy Consumption Forecast by Type (2023-2028)

15.3.2 Global PD-1/PD-L1 Immunotherapy Revenue Forecast by Type (2023-2028)

15.3.3 Global PD-1/PD-L1 Immunotherapy Price Forecast by Type (2023-2028)

15.4 Global PD-1/PD-L1 Immunotherapy Consumption Volume Forecast by Application (2023-2028)

15.5 PD-1/PD-L1 Immunotherapy Market Forecast Under COVID-19

## **CHAPTER 16 CONCLUSIONS**

Research Methodology

## List Of Tables

### LIST OF TABLES AND FIGURES

Figure Product Picture

Figure North America PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure United States PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure Canada PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure Mexico PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure East Asia PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure China PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure Japan PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure South Korea PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure Europe PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure Germany PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure UK PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure France PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure Italy PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure Russia PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure Spain PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure Netherlands PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure Switzerland PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure Poland PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure South Asia PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure India PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure Pakistan PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure Bangladesh PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure Southeast Asia PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure Indonesia PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate

(2023-2028)

Figure Thailand PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate

(2023-2028)

Figure Singapore PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate

(2023-2028)

Figure Malaysia PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate

(2023-2028)

Figure Philippines PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate

(2023-2028)

Figure Vietnam PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate

(2023-2028)

Figure Myanmar PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate

(2023-2028)

Figure Middle East PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate

(2023-2028)

Figure Turkey PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure Saudi Arabia PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate

(2023-2028)

Figure Iran PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure United Arab Emirates PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth

Rate (2023-2028)

Figure Israel PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure Iraq PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure Qatar PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure Kuwait PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure Oman PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure Africa PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure Nigeria PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure South Africa PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate

(2023-2028)

Figure Egypt PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure Algeria PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure Algeria PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure Oceania PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate

(2023-2028)

Figure Australia PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate

(2023-2028)

Figure New Zealand PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate

(2023-2028)

Figure South America PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure Brazil PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure Argentina PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure Columbia PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure Chile PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure Venezuela PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure Peru PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure Puerto Rico PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure Ecuador PD-1/PD-L1 Immunotherapy Revenue (\$) and Growth Rate (2023-2028)

Figure Global PD-1/PD-L1 Immunotherapy Market Size Analysis from 2023 to 2028 by Consumption Volume

Figure Global PD-1/PD-L1 Immunotherapy Market Size Analysis from 2023 to 2028 by Value

Table Global PD-1/PD-L1 Immunotherapy Price Trends Analysis from 2023 to 2028

Table Global PD-1/PD-L1 Immunotherapy Consumption and Market Share by Type (2017-2022)

Table Global PD-1/PD-L1 Immunotherapy Revenue and Market Share by Type (2017-2022)

Table Global PD-1/PD-L1 Immunotherapy Consumption and Market Share by Application (2017-2022)

Table Global PD-1/PD-L1 Immunotherapy Revenue and Market Share by Application (2017-2022)

Table Global PD-1/PD-L1 Immunotherapy Consumption and Market Share by Regions (2017-2022)

Table Global PD-1/PD-L1 Immunotherapy Revenue and Market Share by Regions (2017-2022)

Table 2017-2022 Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin

Figure 2017-2022 Capacity, Production and Growth Rate

Figure 2017-2022 Revenue, Gross Margin and Growth Rate

Table 2017-2022 Major Manufacturers Capacity and Total Capacity

Table 2017-2022 Major Manufacturers Capacity Market Share

Table 2017-2022 Major Manufacturers Production and Total Production



Revenue, Cost, Gross and Gross Margin

Figure 2017-2022 Capacity, Production and Growth Rate

Figure 2017-2022 Revenue, Gross Margin and Growth Rate

Table 2017-2022 Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin

Figure 2017-2022 Capacity, Production and Growth Rate

Figure 2017-2022 Revenue, Gross Margin and Growth Rate

Table Global PD-1/PD-L1 Immunotherapy Consumption by Regions (2017-2022)

Figure Global PD-1/PD-L1 Immunotherapy Consumption Share by Regions (2017-2022)

Table North America PD-1/PD-L1 Immunotherapy Sales, Consumption, Export, Import (2017-2022)

Table East Asia PD-1/PD-L1 Immunotherapy Sales, Consumption, Export, Import (2017-2022)

Table Europe PD-1/PD-L1 Immunotherapy Sales, Consumption, Export, Import (2017-2022)

Table South Asia PD-1/PD-L1 Immunotherapy Sales, Consumption, Export, Import (2017-2022)

Table Southeast Asia PD-1/PD-L1 Immunotherapy Sales, Consumption, Export, Import (2017-2022)

Table Middle East PD-1/PD-L1 Immunotherapy Sales, Consumption, Export, Import (2017-2022)

Table Africa PD-1/PD-L1 Immunotherapy Sales, Consumption, Export, Import (2017-2022)

Table Oceania PD-1/PD-L1 Immunotherapy Sales, Consumption, Export, Import (2017-2022)

Table South America PD-1/PD-L1 Immunotherapy Sales, Consumption, Export, Import (2017-2022)

Figure North America PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)

Figure North America PD-1/PD-L1 Immunotherapy Revenue and Growth Rate (2017-2022)

Table North America PD-1/PD-L1 Immunotherapy Sales Price Analysis (2017-2022)

Table North America PD-1/PD-L1 Immunotherapy Consumption Volume by Types

Table North America PD-1/PD-L1 Immunotherapy Consumption Structure by Application

Table North America PD-1/PD-L1 Immunotherapy Consumption by Top Countries

Figure United States PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Canada PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Mexico PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure East Asia PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)

Figure East Asia PD-1/PD-L1 Immunotherapy Revenue and Growth Rate (2017-2022)

Table East Asia PD-1/PD-L1 Immunotherapy Sales Price Analysis (2017-2022)

Table East Asia PD-1/PD-L1 Immunotherapy Consumption Volume by Types

Table East Asia PD-1/PD-L1 Immunotherapy Consumption Structure by Application

Table East Asia PD-1/PD-L1 Immunotherapy Consumption by Top Countries

Figure China PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Japan PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure South Korea PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Europe PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)

Figure Europe PD-1/PD-L1 Immunotherapy Revenue and Growth Rate (2017-2022)

Table Europe PD-1/PD-L1 Immunotherapy Sales Price Analysis (2017-2022)

Table Europe PD-1/PD-L1 Immunotherapy Consumption Volume by Types

Table Europe PD-1/PD-L1 Immunotherapy Consumption Structure by Application

Table Europe PD-1/PD-L1 Immunotherapy Consumption by Top Countries

Figure Germany PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure UK PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure France PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Italy PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Russia PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Spain PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Netherlands PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Switzerland PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Poland PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure South Asia PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)

Figure South Asia PD-1/PD-L1 Immunotherapy Revenue and Growth Rate (2017-2022)

Table South Asia PD-1/PD-L1 Immunotherapy Sales Price Analysis (2017-2022)

Table South Asia PD-1/PD-L1 Immunotherapy Consumption Volume by Types

Table South Asia PD-1/PD-L1 Immunotherapy Consumption Structure by Application

Table South Asia PD-1/PD-L1 Immunotherapy Consumption by Top Countries

Figure India PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Pakistan PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Bangladesh PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Southeast Asia PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)

Figure Southeast Asia PD-1/PD-L1 Immunotherapy Revenue and Growth Rate (2017-2022)

Table Southeast Asia PD-1/PD-L1 Immunotherapy Sales Price Analysis (2017-2022)

Table Southeast Asia PD-1/PD-L1 Immunotherapy Consumption Volume by Types

Table Southeast Asia PD-1/PD-L1 Immunotherapy Consumption Structure by Application

Table Southeast Asia PD-1/PD-L1 Immunotherapy Consumption by Top Countries

Figure Indonesia PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Thailand PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Singapore PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Malaysia PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Philippines PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Vietnam PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Myanmar PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Middle East PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)

Figure Middle East PD-1/PD-L1 Immunotherapy Revenue and Growth Rate (2017-2022)

Table Middle East PD-1/PD-L1 Immunotherapy Sales Price Analysis (2017-2022)

Table Middle East PD-1/PD-L1 Immunotherapy Consumption Volume by Types

Table Middle East PD-1/PD-L1 Immunotherapy Consumption Structure by Application

Table Middle East PD-1/PD-L1 Immunotherapy Consumption by Top Countries

Figure Turkey PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Saudi Arabia PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Iran PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure United Arab Emirates PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Israel PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Iraq PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Qatar PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Kuwait PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Oman PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Africa PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)

Figure Africa PD-1/PD-L1 Immunotherapy Revenue and Growth Rate (2017-2022)

Table Africa PD-1/PD-L1 Immunotherapy Sales Price Analysis (2017-2022)

Table Africa PD-1/PD-L1 Immunotherapy Consumption Volume by Types

Table Africa PD-1/PD-L1 Immunotherapy Consumption Structure by Application

Table Africa PD-1/PD-L1 Immunotherapy Consumption by Top Countries

Figure Nigeria PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure South Africa PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Egypt PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Algeria PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Algeria PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Oceania PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)

Figure Oceania PD-1/PD-L1 Immunotherapy Revenue and Growth Rate (2017-2022)

Table Oceania PD-1/PD-L1 Immunotherapy Sales Price Analysis (2017-2022)

Table Oceania PD-1/PD-L1 Immunotherapy Consumption Volume by Types

Table Oceania PD-1/PD-L1 Immunotherapy Consumption Structure by Application

Table Oceania PD-1/PD-L1 Immunotherapy Consumption by Top Countries

Figure Australia PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure New Zealand PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure South America PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)

Figure South America PD-1/PD-L1 Immunotherapy Revenue and Growth Rate (2017-2022)

Table South America PD-1/PD-L1 Immunotherapy Sales Price Analysis (2017-2022)

Table South America PD-1/PD-L1 Immunotherapy Consumption Volume by Types

Table South America PD-1/PD-L1 Immunotherapy Consumption Structure by Application

Table South America PD-1/PD-L1 Immunotherapy Consumption Volume by Major Countries

Figure Brazil PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Argentina PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Columbia PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Chile PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Venezuela PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Peru PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Puerto Rico PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022

Figure Ecuador PD-1/PD-L1 Immunotherapy Consumption Volume from 2017 to 2022  
AstraZeneca Plc PD-1/PD-L1 Immunotherapy Product Specification  
AstraZeneca Plc PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2017-2022)  
Innovent Biologics, Inc. PD-1/PD-L1 Immunotherapy Product Specification  
Innovent Biologics, Inc. PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2017-2022)  
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1/PD-L1 Immunotherapy Product Specification  
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2017-2022)  
BeiGene, Ltd. PD-1/PD-L1 Immunotherapy Product Specification  
Table BeiGene, Ltd. PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2017-2022)  
GlaxoSmithKline plc PD-1/PD-L1 Immunotherapy Product Specification  
GlaxoSmithKline plc PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2017-2022)  
Bristol-Myers Squibb Company PD-1/PD-L1 Immunotherapy Product Specification  
Bristol-Myers Squibb Company PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2017-2022)  
Merck & Co., Inc. PD-1/PD-L1 Immunotherapy Product Specification  
Merck & Co., Inc. PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2017-2022)  
F. Hoffmann-La Roche Ltd PD-1/PD-L1 Immunotherapy Product Specification  
F. Hoffmann-La Roche Ltd PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2017-2022)  
Eli Lilly & Company PD-1/PD-L1 Immunotherapy Product Specification  
Eli Lilly & Company PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2017-2022)  
Jiangsu HengRui Medicine Co., Ltd. PD-1/PD-L1 Immunotherapy Product Specification  
Jiangsu HengRui Medicine Co., Ltd. PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2017-2022)  
Novartis AG PD-1/PD-L1 Immunotherapy Product Specification  
Novartis AG PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2017-2022)  
Sanofi S.A. PD-1/PD-L1 Immunotherapy Product Specification  
Sanofi S.A. PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2017-2022)  
Pfizer Inc. PD-1/PD-L1 Immunotherapy Product Specification

Pfizer Inc. PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2017-2022)

Regeneron Pharmaceuticals Inc. PD-1/PD-L1 Immunotherapy Product Specification

Regeneron Pharmaceuticals Inc. PD-1/PD-L1 Immunotherapy Production Capacity, Revenue, Price and Gross Margin (2017-2022)

Figure Global PD-1/PD-L1 Immunotherapy Consumption Volume and Growth Rate Forecast (2023-2028)

Figure Global PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Table Global PD-1/PD-L1 Immunotherapy Consumption Volume Forecast by Regions (2023-2028)

Table Global PD-1/PD-L1 Immunotherapy Value Forecast by Regions (2023-2028)

Figure North America PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure North America PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure United States PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure United States PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure Canada PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure Canada PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure Mexico PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure Mexico PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure East Asia PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure East Asia PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure China PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure China PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure Japan PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure Japan PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast

(2023-2028)

Figure South Korea PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure South Korea PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure Europe PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure Europe PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure Germany PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure Germany PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure UK PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure UK PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure France PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure France PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure Italy PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure Italy PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure Russia PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure Russia PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure Spain PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure Spain PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure Netherlands PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure Netherlands PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure Switzerland PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure Switzerland PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure Poland PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure Poland PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure South Asia PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure South Asia a PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure India PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure India PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure Pakistan PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure Pakistan PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure Bangladesh PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure Bangladesh PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure Southeast Asia PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure Southeast Asia PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure Indonesia PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure Indonesia PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure Thailand PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure Thailand PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure Singapore PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure Singapore PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure Malaysia PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure Malaysia PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure Philippines PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure Philippines PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure Vietnam PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure Vietnam PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure Myanmar PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure Myanmar PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure Middle East PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure Middle East PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure Turkey PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure Turkey PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure Saudi Arabia PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure Saudi Arabia PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure Iran PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure Iran PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure United Arab Emirates PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure United Arab Emirates PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure Israel PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure Israel PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure Iraq PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure Iraq PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure Qatar PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast

(2023-2028)

Figure Qatar PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast

(2023-2028)

Figure Kuwait PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast

(2023-2028)

Figure Kuwait PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast

(2023-2028)

Figure Oman PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast

(2023-2028)

Figure Oman PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast

(2023-2028)

Figure Africa PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast

(2023-2028)

Figure Africa PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast

(2023-2028)

Figure Nigeria PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast

(2023-2028)

Figure Nigeria PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast

(2023-2028)

Figure South Africa PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure South Africa PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast

(2023-2028)

Figure Egypt PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast

(2023-2028)

Figure Egypt PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast

(2023-2028)

Figure Algeria PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast

(2023-2028)

Figure Algeria PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast

(2023-2028)

Figure Morocco PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast

(2023-2028)

Figure Morocco PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast

(2023-2028)

Figure Oceania PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast

(2023-2028)

Figure Oceania PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast

(2023-2028)

Figure Australia PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure Australia PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure New Zealand PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure New Zealand PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure South America PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure South America PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure Brazil PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure Brazil PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure Argentina PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure Argentina PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure Columbia PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure Columbia PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure Chile PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure Chile PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure Venezuela PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure Venezuela PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure Peru PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure Peru PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure Puerto Rico PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast (2023-2028)

Figure Puerto Rico PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast (2023-2028)

Figure Ecuador PD-1/PD-L1 Immunotherapy Consumption and Growth Rate Forecast

(2023-2028)

Figure Ecuador PD-1/PD-L1 Immunotherapy Value and Growth Rate Forecast

(2023-2028)

Table Global PD-1/PD-L1 Immunotherapy Consumption Forecast by Type (2023-2028)

Table Global PD-1/PD-L1 Immunotherapy Revenue Forecast by Type (2023-2028)

Figure Global PD-1/PD-L1 Immunotherapy Price Forecast by Type (2023-2028)

Table Global PD-1/PD-L1 Immunotherapy Consumption Volume Forecast by  
Application (2023-2028)

## I would like to order

Product name: 2023-2028 Global and Regional PD-1/PD-L1 Immunotherapy Industry Status and Prospects Professional Market Research Report Standard Version

Product link: <https://marketpublishers.com/r/2BC0A8B7FDD0EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2BC0A8B7FDD0EN.html>